NASDAQ:AVEO AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free AVEO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.99▼$15.0050-Day Range$14.90▼$15.0052-Week Range$3.06▼$15.00Volume247,800 shsAverage Volume601,442 shsMarket Capitalization$521.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AVEO Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Read More Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) AVEO Stock News HeadlinesMarch 25, 2024 | finanznachrichten.deAVEO Pharmaceuticals, Inc.: AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 25, 2024 | globenewswire.comAVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 12, 2024 | finance.yahoo.comNeuroendocrine Tumor Treatment Market revenue to hit USD 8 Billion by 2035, says Research NesterMarch 6, 2024 | msn.com2024 Chevrolet Aveo: Driving The Compact Expat In Mexico CityNovember 30, 2023 | finance.yahoo.comAVEO Oncology, an LG Chem company, Earns Spot on Boston Globe's 2023 Top Places to Work List for Second Consecutive YearNovember 3, 2023 | finance.yahoo.comActinium Appoints Lynn Bodarky as Chief Business OfficerOctober 30, 2023 | afr.comBrookfield finalises $1.45b debt refi for Aveo; lenders pile inMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…July 13, 2023 | afr.comBrookfield locks in $1.45b debt refi for Aveo; five banks underwriteMay 10, 2023 | finance.yahoo.comActinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals DayMay 5, 2023 | marketwatch.com2023 Kidney Cancer Market Size Growth Analysis by Absolute Reports | with [101 Pages] and Forecast till 2031May 3, 2023 | marketwatch.comC-MET & HGF Inhibitors Market Growth Opportunities and Emerging Trends till 2031May 3, 2023 | marketwatch.comFGF-2 Inhibitors Market 2023 SWOT Analysis and Demand Status Forecast by 2030April 27, 2023 | marketwatch.comC-MET / HGF Inhibitors Market Size [2023] Global Overview includes Market Trends and Forecast to 2027 | with [148 Pages]April 27, 2023 | marketwatch.comHepatocyte Growth Factor Market Research Analysis 2023-2031April 25, 2023 | marketwatch.comNeuroendocrine Tumors Treatment Market 2023 to 2030 Market Analysis, Share, Size, Trends, Scope, Growth Drivers, By Top Companies And ForecastApril 23, 2023 | marketwatch.com2023-2030 Kidney Cancer Treatment Drugs Market Share, Detailed Examination of Industry Trends and OpportunitiesApril 20, 2023 | marketwatch.comIndustry Research Report on C-MET / HGF Inhibitors Market Share and Industrial Overview till 2030April 16, 2023 | marketwatch.comC-MET / HGF Inhibitors Market Forecast to 2030April 14, 2023 | msn.com2024 Chevy Aveo: The Sonic Is Still Alive and Thriving, Just Not in the U.S.April 12, 2023 | marketwatch.comC-MET & HGF Inhibitors Market Growth by 2030April 7, 2023 | marketwatch.com2023 Cancer Drug Therapy Market: Projection up to 2027April 5, 2023 | marketwatch.comKidney Cancer Drugs Market 2023 Size and Forecast to 2031April 3, 2023 | thestreet.comAVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing AgreementMarch 21, 2023 | marketwatch.comCancer Drug Therapy Market Size and Forecast till 2028March 17, 2023 | marketwatch.comKidney Cancer Market 2023 Exploring New Challenges and Opportunities, Forecast to 2028See More Headlines Receive AVEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AVEO CUSIP05358810 CIK1325879 Webwww.aveooncology.com Phone(617) 400-0101Fax617-995-4995Employees114Year Founded2001Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,340,000.00 Net Margins-30.79% Pretax Margin-30.79% Return on Equity-81.66% Return on Assets-28.83% Debt Debt-to-Equity Ratio0.94 Current Ratio2.37 Quick Ratio2.35 Sales & Book Value Annual Sales$42.29 million Price / Sales12.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book11.28Miscellaneous Outstanding Shares34,763,000Free Float33,619,000Market Cap$521.45 million OptionableOptionable Beta1.00 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMichael P. BaileyPresident, Chief Executive Officer & DirectorJebediah LedellChief Operating OfficerErick J. LuceraChief Financial OfficerMatthew CoulterVice President-Information TechnologyStefanie SolomonHead-ComplianceKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXOPKO HealthNASDAQ:OPKVerastemNASDAQ:VSTMXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLView All Competitors AVEO Stock Analysis - Frequently Asked Questions How were AVEO Pharmaceuticals' earnings last quarter? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) posted its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to analysts' expectations of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. During the same period in the previous year, the firm earned ($0.33) earnings per share. When did AVEO Pharmaceuticals' stock split? Shares of AVEO Pharmaceuticals reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO? 4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend. What other stocks do shareholders of AVEO Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA). Who are AVEO Pharmaceuticals' major shareholders? AVEO Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Michael Ferraresso and Michael P Bailey. View institutional ownership trends. This page (NASDAQ:AVEO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVEO Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.